TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Maximum observed serum concentration of ipilimumab (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Factor VIII (FVIII) Activity Levels Assessed by One-Stage Coagulation Assay (OSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Spontaneous Bleeds Annualized Bleeding Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Colorectal cancer screening compliance
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Microbicide use adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Microbicide use acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Microbicide use attitudes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ROM assessment of iliopsoas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: ROM assessment of rectus femoris
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: ROM assessment of hamstrings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: ROM assessment of erector spinae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in overeating
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Incidence of nosocomial COVID-19
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Reported Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Childbirth Comfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Kinematic and kinetic data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Complete Response (CR) or Partial Response (PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Infection With RSV Vaccine Virus
Endpoint domain: Adverse events/effects
Primary endpoint: Change in serum levels of polychlorinated biphenyls
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum levels of hydroxylated metabolites of polychlorinated biphenyls
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum levels of organochlorine pesticides
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma levels of heat shock protein (HSP 70), HMGB1, S100A9 and IL-33
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac arrest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Salivary Cortisol (Diurnal)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Depression (Beck Depression Inventory)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Anxiety (Beck Anxiety Inventory)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: VAP Incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of study subjects with diagnosis of Narcolepsy type 1 (NT1) at follow up
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of study subjects with final diagnosis other than NT1 but within the group of CDH at follow up
Endpoint domain: Mortality/survival
Primary endpoint: Avoidance of arthroplasty
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time in ranges
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in induced sputum differential neutrophil count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With a Positive bHCG Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in baseline scores of qualitative questionnaires
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cognitive theory of mind first order
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emotional regulation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Self Esteem
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of device related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement of AOFAS HMIS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under plasma TAG concentration/time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevalence of SCD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients Who Tolerate Buprenorphine Initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Achieve Opioid Cessation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: minutes of moderate-intensity physical activity per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: exercise in MET-hrs/week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of condition after surgery
Endpoint domain: Mortality/survival
Primary endpoint: Change in Child Protection
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Exposure to Child Abuse
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Number of Participants With Detectable C. Difficile
Endpoint domain: Adverse events/effects
Primary endpoint: Clinically Significant Improvement in Outcomes
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of patients who avoided surgery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: CDAI of 150 or less
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Carotid Intima Media Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Immune cell activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change of cerebral tissue oxygen saturation (crSO2) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom Index (SI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Symptom Associated Probability (SAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Acute infection by SARS-CoV-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Sickle cell nephropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: 48 month PSA values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Safety of ULD IL-2
Endpoint domain: Adverse events/effects
Primary endpoint: relapse-free survival time/rate
Endpoint domain: Mortality/survival
Primary endpoint: Safety Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Tolerated Dose (MTD) of Taxotere
Endpoint domain: Adverse events/effects
Primary endpoint: Change in TOMM20 and MCT4 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Curve Versus Time at a Dosing Interval at Steady State (AUCtau)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Concentration (Cmean,ss) of Tadalafil at Steady-State
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of IV CBZ
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetics of IV CBZ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in QOL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in symptom intensity and distress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in performance on Action Research Arm Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in performance on Chedoke Arm and Hand Inventory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in status on Stroke Impact Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: specificity of responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: test reliability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Annualized Coronary Calcium Volume Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Resistance and compliance during ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of caries in primary teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RBANS Total Index Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: QTci intervals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Full BLS performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral embolic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevalence of Penicillin allergy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Negative predictive value of the allergy work-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety of poly ICLC (Hiltonol)
Endpoint domain: Adverse events/effects
Primary endpoint: Geometric mean concentration of anti-hepatitis B virus surface antigen antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: AUC0-inf under fasting conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax under fasting conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ctrough (Ct) under fasting conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-inf under fed conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax under fed conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ctrough (Ct) under fed conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of the peak of ankle negative power during the weight acceptance phase of gait
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of the peak of trunk's anterior deceleration during the weight acceptance phase of gait
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of the peak of the center of mass downward deceleration during the weight acceptance phase of gait
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cochlear implant electrode location after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complications assessed by aldrete score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Toxicity (pneumonitis)
Endpoint domain: Adverse events/effects
Primary endpoint: Good response to hMG therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change from baseline in the number of inflammatory lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement from baseline in global severity
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Hostility Bias score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Drug safety (absence of severe adverse effects)
Endpoint domain: Adverse events/effects
Primary endpoint: Successful treatment outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BFI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Net oxygen cost (OC, ml/kg/m)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Net heart rate (HR, beats/min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Net minute ventilation (VE, L/min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Participants With Majority Reader Self-agreement in Ischemia Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in fruit and vegetable intake
Endpoint domain: Life impact
Endpoint subdomain: Nutrition
Primary endpoint: Change in urine albumin-to-creatinine ratio (ACR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Expression of CXCR3 in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Levels of chemokines IL-4, IFN-γ, CXCL9, CXCL10, CXCL11, and CCL17 in sputum and blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: PImax and Hand Grip Force correlation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PEmax and Hand Grip Force correlation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Referral Disparity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Recovery status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma vitamin K2 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinician Administered Dissociative Symptoms Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of daptomycin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants That Discontinued Due to Adverse Experience
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Experiencing Serious or Unexpected Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Quadriceps Muscle Activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in Total Cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in LDL-C (LDL Low Density Lipoprotein-cholesterol)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Parasite Reduction Ratio (PRR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Clinically-suspected Biopsy-proven Acute Rejection (CSBPAR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Physical activity Level
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Subjects With Anti-diphtheria Antibody Concentrations ≥ Protocol Specified Cut-off
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects With Anti-tetanus Antibody Concentrations ≥ Protocol Specified Cut-off
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Booster Response to D and T Antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement in health-related quality of life (HRQOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Survival after hematopoietic cell transplantation (HCT)
Endpoint domain: Mortality/survival
Primary endpoint: Change in HRQOL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Perioperative electrocardiogram changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of responders (complete remission without corticosteroids)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Creatinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Gains in visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Steroid dosage required to control brain edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: cerebral vasospasm indices (incidence, onset, severity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Post operative pain level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Event-free at 12 Months
Endpoint domain: Mortality/survival
Primary endpoint: Amount of Testosterone MD-Lotion 2% remaining on the axilla
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mammographic breast density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Breast outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of Capecitabine When Combined With Trastuzumab Emtansine
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Best Overall Response (BOR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative opioid consumption (morphine equivalents)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lung Resection Surgery within 4 months of diagnosis
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Completion of surgery, radiation, and adjuvant chemotherapy within 6 months of diagnosis
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Diabetes mellitus (Incident cases)
Endpoint domain: Mortality/survival
Primary endpoint: Myocardial infarction (Incident cases)
Endpoint domain: Mortality/survival
Primary endpoint: incidence of treatment-emergent/related adverse events and serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: laboratory abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: nadir of myelosuppression
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Alkaline Phosphatase (ALP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Diagnostic accuracy of multiparametric MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myeloma response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Serum Hepatitis B Surface Antigen (HBsAg) Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Adverse Events Leading to Permanent Discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Change of signal intensity in CMR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corticosteroid Taper Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chronotropic Incompetence Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fistulation rate
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Patient-reported Worst Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Self-reported Falls
Endpoint domain: Adverse events/effects
Primary endpoint: chronic systemic inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systemic clearance of fentanyl and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with non-serious and serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects with improvement on the patient impression of improvement questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Average Mean Arterial Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum Voluntary Contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Precision Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endurance Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful cleansing rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum and plasma levels of free Vascular Endothelial Growth Factor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart Rate changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of Lazertinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve from Time 0 to 120 Hours (AUC [0-120h]) of Lazertinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve from Time Zero to Infinity (AUC [0-inf]) of Lazertinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes